Briviact* (Brivaracetam) — Medicare Part D spending
UCB Pharma* · Rank #241 by total Part D spend · CMS data year 2023
Medicare Part D spent $184,375,922 on Briviact* (Brivaracetam) in 2023, the #241 drug by total Part D spending out of 3,598 drugs. That worked out to about $23.49 per dosage unit, $1,627 per claim and $14,370 per beneficiary, across 113,292 claims for 12,831 beneficiaries. Average spending per dosage unit rose +6.6% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Briviact* (Brivaracetam) spending at a glance (2023)
| Metric | Briviact* (Brivaracetam) |
|---|---|
| Total Part D spending (2023) | $184,375,922 |
| Total spending (2022) | $149,528,079 |
| Year-over-year change in total spending | +23.3% |
| Average spending per dosage unit (2023) | $23.49 |
| Change in spend per dosage unit (YoY) | +6.6% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +5.4% |
| Average spending per claim (2023) | $1,627 |
| Average spending per beneficiary (2023) | $14,370 |
| Total claims (2023) | 113,292 |
| Beneficiaries (2023) | 12,831 |
| Total dosage units (2023) | 9,434,510 |
| Manufacturer(s) | UCB Pharma* |
| National rank by total spend (of 3,598 drugs) | #241 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $149,528,079 | $184,375,922 | +23.3% |
| Avg spend per dosage unit | $22.04 | $23.49 | +6.6% |
| Avg spend per claim | $1,508 | $1,627 | — |
| Avg spend per beneficiary | $13,469 | $14,370 | — |
| Total claims | 99,139 | 113,292 | — |
| Beneficiaries | 11,102 | 12,831 | — |
How Briviact* compares with nearby drugs
Drugs with total Part D spending closest to Briviact* (Brivaracetam):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Briviact* (Brivaracetam) (this drug, #241) | $184,375,922 | $23.49 | +6.6% |
| Actemra Actpen (Tocilizumab) (#239) | $184,648,416 | $1,330.09 | +6.8% |
| Tibsovo (IVosidenib) (#240) | $184,488,983 | $549.19 | +6.7% |
| Levemir Flextouch (Insulin Detemir) (#242) | $184,280,489 | $32.54 | +0.8% |
| Pravastatin Sodium (#243) | $183,603,098 | $0.26 | +8.3% |
| Auryxia (Ferric Citrate) (#244) | $182,627,699 | $7.89 | +7.7% |
Frequently asked questions
How much does Medicare Part D spend on Briviact*?
Medicare Part D spent $184,375,922 on Briviact* (Brivaracetam) in 2023 (the latest CMS data year), across 113,292 claims for 12,831 beneficiaries. That ranks #241 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Briviact*?
In 2023, the weighted average Medicare Part D spending per dosage unit for Briviact* (Brivaracetam) was $23.49. Compared with 2022 it rose +6.6%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Briviact*?
CMS attributes Briviact* (Brivaracetam) to UCB Pharma* in the 2023 Part D spending file. Average spending per claim was $1,627 and per beneficiary $14,370.
Is the Briviact* figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20